Biogen Inc. (BIIB) vs Sanofi (SNY)
Biogen Inc. and Sanofi are both Drug Manufacturers General companies. Sanofi is the larger, with a market value of $97.4B against $33.5B — 2.9× the size. Sanofi trades at the lower P/E: 21.5× against 40.1×. Sanofi grew revenue faster over the last twelve months: 21.3% against 0.31%. Biogen Inc. has the higher net margin (8.32% vs 8.22%) and the lower return on invested capital (3.11% vs 6.58%). Across the 22 metrics below, Sanofi leads on 19 and Biogen Inc. on 3.
Valuation
Profitability
| Metric | BIIB | SNY | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 73.99% | 72.78% | 72.77% |
| Operating margin | 12.35% | 18.24% | 18.90% |
| Net margin | 8.32% | 8.22% | 8.27% |
| Free cash flow margin | 25.33% | 25.53% | 17.25% |
| Return on equity | 4.58% | 5.87% | 6.97% |
| Return on assets | 2.76% | 3.21% | 2.76% |
| Return on invested capital | 3.11% | 6.58% | 6.30% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack